|Bid||48.53 x 800|
|Ask||48.57 x 1000|
|Day's range||46.47 - 49.00|
|52-week range||36.48 - 58.25|
|Beta (5Y monthly)||0.68|
|PE ratio (TTM)||17.65|
|Earnings date||08 Aug 2022 - 12 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||48.50|
WOODCLIFF LAKE, N.J., May 26, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the William Blair 42nd Annual Growth Stock Conference as follows: Date:Thursday, June 9, 2022 Time:9:40AM ET/8:40AM CT Webcast:Click Here About Eagle Pharmaceuticals, Inc. Eagle is a fully integrated pharmaceutical company with research and development, clin
For many, the main point of investing is to generate higher returns than the overall market. But even the best stock...
At this time, I'd like to welcome everyone to Eagle Pharmaceuticals first quarter 2022 financial results. It is now my pleasure to turn the floor over to Ms. Lisa Wilson, investor relations for Eagle Pharmaceuticals.